Skip to main content

Ovarian Cancer Diagnostics Sales Set to Rise with Concentrated Investment by Market Players, details Fact.MR report

Fact.MR has published a new research report on global ovarian cancer diagnostics market sizes, upcoming industry trends and growth opportunity through 2018-2028 to its online database that tries to unveil the various scenarios prevailing in the ovarian cancer diagnostics market. This assessment delivers a smart compilation of primary and secondary data which provides a clear insight about the future plans expected to impact the ovarian cancer diagnostics market. This study comprises of prominent data which makes it a beneficial source for investors, analysts and industry experts to acquire necessary knowledge associated to the fundamental market trends, opportunities and growth drivers during the stated forecast by 2028.
Ovarian cancer is developed by uncontrollable growth of cells in ovaries. Made up of three different types of cells, ovaries may develop three different types of tumors. Majority of these tumors are non-cancerous, which can be treated by removing either part of the ovary containing the tumor, or by removing the ovary itself. The American Cancer Society estimates that approx. 20,000 women will be diagnosed with ovarian cancer in the U.S. and more than 14,000 will lose their lives because of it in 2017 alone. In terms of deaths, this form of cancer ranks fifth and it led to more deaths than any other female reproductive system form of cancer. The chance of a women developing ovarian cancer during her life is 1 in 75 and the chance of her dying is 1 in 100. It is mainly seen in older women above the age of 63 years. Even though the rate at which women have been diagnosed with ovarian cancer has been falling, it is still a public health menace that needs to be tackled effectively. This is where the ovarian cancer diagnostics market can play a crucial role. The global ovarian cancer diagnostics market is predicted to grow with a CAGR of 8.7% and be worth nearly US$ 1 billion in 2022, from less than US$ 640 million in 2017.
Epithelial Tumours Segment larger than the other two combined
The Epithelial Tumours Segment is anticipated to grow to almost US $ 880 million by the end of the forecast period and it already accounts for an 11% revenue share in 2017 itself.  North America alone represents almost 2/5th of the market and it should touch US$ 330 million by the end of 2022. The germ cell carcinoma tumours segment is much smaller by comparison and is only poised to be a US$ 50 million market by the end of the five year study. Even the stromal carcinoma tumours segment is marginal at best when contrasted with epithelial tumours in the ovarian cancer diagnostics market. The stromal carcinoma tumours segment is likely to be valued at only US$ 28 million in 2017.
The hospital associated lab segment is expected to record a CAGR of 7.8% from 2017-2022 and rise from just under $300 million in 2017 to roughly US$ 440 million in 2022. Independent diagnostic labs are the second most important segment in the ovarian cancer diagnostics market and are estimated to be worth US$ 161 million in 2017. While North America might account for the largest contribution, Europe should record a higher CAGR of 9.5% making it more attractive to target in the long term.
Focus on CA 125 test segment in the ovarian cancer diagnostics market
The CA 125 test segment could be worth roughly US$ 440 million in 2022 and some key stakeholders may decide to focus on this lucrative test over all other available alternatives in the ovarian cancer diagnostics market. However, the HER 2 segment also accounts for a 3.1% revenue share in 2017 and it would be unwise to do so. On the other hand, the BRCA segment in North America alone could grow with a CAGR of 8.3% for the period 2017-2022, making it imperative for companies to hedge their bets in the ovarian cancer diagnostics market.
Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=51
The report has also profiled leading players in the global market for ovarian cancer diagnostics, which include Quest Diagnostics Incorporated, Myriad Genetics Inc., AstraZeneca plc., Epigenomics AG, Illumina, Inc., Bio-Rad Laboratories, Inc., Siemens AG, Thermo Fisher Scientific Inc., Roche Holding AG., and Abbott Laboratories.
Labels:

Comments

Post a Comment

Popular posts from this blog

Electrosurgery Devices Market: Radiofrequency Electrosurgery Devices will Remain the Top-Selling Product

On the back of rising ageing population, increased instances of surgical procedures and technological innovations, the market for electrosurgical devices is likely to slate lucrative growth triggers in the coming years. Significant spike in surgical procedures pertaining neurology, cardiology, gynecology, and several other general surgeries, electrosurgery devices market is in the cusp of exponential growth. Owing to technological innovations the electrosurgery market in North America has demonstrated growth traction over the years. However, increased healthcare spending towards minimally invasive treatment in Asia-Pacific region is expected to propel the market forward, thus contributing as one of the fastest regional hub in electrosurgery devices market. However, factors such as significant product recalls owing to incompliance with FDA framework remain potential challenges for the growth trajectory. Get sample of this report at https://www.factmr.com/connectus/sample?flag=S...
Post a Comment
Read more

North America to Maintain its Leader Status for the Dermatology Devices Market

 Increasing geriatric population across the world have propelled the demand for the dermatology devices, which in turn has contributed to the growth of the dermatology devices market. Rising adoption of dermatology devices in parallel to the rapid adoption of technology in the dermatology clinics and hospitals for treating skin disorders have been prominent factors for the growth of dermatology devices market. Spur in the spending capability of consumers have facilitated the access to these devices. Pervasiveness of skin disorders has been rising at the global level, which has created demand for acute treatment devices. Developments in the treatment methodologies such as liposuction devices and laser instruments have been successful in attracting the attention of the consumers. A recent report published by Fact.MR states that the global dermatology devices market is anticipated to surpass the whopping value of US$ 1,000 Mn by 2022. Browse Full Report with TOC 'https://www.factm...
Post a Comment
Read more

Lithotripsy Devices Market: Non-Invasive ESWL Witnessing Immense Traction

The report offers a crisp overview of the lithotripsy devices market, which includes an introduction to the lithotripsy devices market in tandem with a definition of the target product – lithotripsy devices. A systematic breakdown of the lithotripsy devices market has been offered in this chapter, which implies scope of the research involved. Size of lithotripsy devices market has been studied in terms of volume (tons) and value (MN), and forecast on the lithotripsy devices market has been offered for the period between 2018 and 2026. The lithotripsy devices market is projected to continue its steady growth due to the burgeoning cases of kidney stones, coupled with the surging demand for minimally invasive medical treatments. According to Fact.MR report, the  lithotripsy devices market  is anticipated to accelerate at 4.3% CAGR during 2018-2026 to reach a value of US$ 1,095.2 MN by the end of 2026. In recent past, lithotripsy has become the most pref...
Post a Comment
Read more